about
Horizons in therapy for corneal angiogenesis.Candidate gene studies of diabetic retinopathy in humanAttenuation of diabetic retinopathy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic ratsTargeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivoApelin is required for non-neovascular remodeling in the retina.Regulation of Tumor Angiogenesis and Choroidal Neovascularization by Endogenous Angioinhibitors.Triamcinolone acetonide as an adjunct to bevacizumab for prevention of corneal neovascularization in a rat modelGlycobiology of ocular angiogenesis.Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization.Nanoceria inhibit expression of genes associated with inflammation and angiogenesis in the retina of Vldlr null mice.Exploring leptin antagonism in ophthalmic cell modelsEffect of LLLT on endothelial cells culture.Polymorphisms in the vascular endothelial growth factor gene and the risk of diabetic retinopathy in Chinese patients with type 2 diabetes.Thrombospondin-1-Based Antiangiogenic Therapy.Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye diseaseHemangiogenesis and lymphangiogenesis in corneal pathology.Genetic modification of corneal neovascularization in Dstn (corn1) mice.Rapidly dissolving polymeric microneedles for minimally invasive intraocular drug deliveryRole of long non-coding RNA-RNCR3 in atherosclerosis-related vascular dysfunction.MicroRNA signature and function in retinal neovascularization.Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab.Emerging techniques to treat corneal neovascularisationNatural product inhibitors of ocular angiogenesis.Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye.Serial optical coherence tomography angiography for corneal vascularization.Integrative analysis of ocular complications in atherosclerosis unveils pathway convergence and crosstalk.Design and in vitro biocompatibility of a novel ocular drug delivery device.Effects of GH/IGF-I Axis on Retinal Vascular Morphology: Retinal Vascular Characteristics in a Clinical Setting with Severe IGF-I Deficiency.S100A proteins in the pathogenesis of experimental corneal neovascularization.Silencing Of Circular RNA-ZNF609 Ameliorates Vascular Endothelial Dysfunction.Decoding Noncoding RNAs: Role of MicroRNAs and Long Noncoding RNAs in Ocular Neovascularization.Retinopathy of prematurity: inflammation, choroidal degeneration, and novel promising therapeutic strategies.Targeting of integrin-linked kinase with small interfering RNA inhibits VEGF-induced angiogenesis in retinal endothelial cells.Genetic polymorphisms of vascular endothelial growth factor and risk for retinopathy of prematurity in South of Iran.Allograft survival enhancement using doxycycline in alkali-burned mouse corneas.Epigalloccatechin-3-gallate inhibits ocular neovascularization and vascular permeability in human retinal pigment epithelial and human retinal microvascular endothelial cells via suppression of MMP-9 and VEGF activation.Suppression of corneal neovascularization by curcumin via inhibition of Wnt/β-catenin pathway activation.Angiogenesis and lymphangiogenesis in corneal transplantation-A review.LncRNA-RP11-714G18.1 suppresses vascular cell migration via directly targeting LRP2BP.Glucocorticoid receptor signaling in the eye.
P2860
Q27691454-1D920E1E-2F56-408D-AEAA-402FFBF7A457Q28073127-D91381CF-1A5B-4CBE-AB53-00CEBFC670A6Q33793466-E720E39E-5BDF-48DE-8C18-A1463DAF0F04Q34062422-646341EA-D048-4AA7-A516-7F0250B52737Q34070170-2437F3BC-CB87-4FAF-A7D8-9143DF7462B0Q34230899-0C322AB2-10E4-4D16-9752-4DE9746A4438Q34272294-16D95687-7FD8-4F7E-B8F3-3329CD8B9F21Q34414227-30817ECB-6A4B-46C8-83CD-15CCD1229404Q34511156-E21CBBFC-89BB-4940-8479-A89442986309Q34678965-830957B4-51A7-4A01-87F8-AC724F8A1371Q35009436-B08258F7-482A-4C22-BD63-2C813D588E8DQ35260184-FE976D8D-C76B-4E0A-86C5-414DEAC01C8BQ35600012-336B0604-670B-4AAF-A07C-367430678F3DQ36417463-E2A30581-82CF-4F5F-8226-31E7026BF921Q36776787-A526A140-7BEB-4495-BB16-9625D10A50A2Q37010132-B6277F78-862A-44B4-B02C-68593ECA9712Q37242535-9EAED4EF-B7FC-4397-84B3-6E1ABE043B6CQ37396059-28D7AD3B-8036-448E-B1B6-CAAF548BE8C2Q37482738-16F8FAFC-2B52-41A5-9224-D68549ACD86EQ37617260-310C7FEE-5546-4B1F-AB2B-B32FC6ECCD84Q37693888-37F26570-D6FE-4B5A-B586-1343346FBAFAQ37943247-33337F96-CABF-4ACA-8733-BB2B1C98F97AQ38258984-B002B166-CFF2-4E67-BE35-53CED31DE3FFQ38279950-A563C84C-B051-4F39-881D-34005641AF03Q38813124-D0F38370-029E-4BFF-B53E-111D148B3646Q39155136-A4DD31B1-3B1A-44A2-BBDC-DAF584C42FFEQ39870330-5D74999C-8F26-4F8F-BE64-9B9FF4DE196BQ40211388-CDE7E66C-461B-447F-AD6A-54C22788E09BQ41395501-367CAF42-E969-48A1-9750-85E3404566A8Q41455499-B3C5353A-2D53-46E2-9603-56049A806342Q41481594-7B9143E3-F7C5-4F71-815F-7B2521DDF443Q41494887-9530C0C2-F96F-43E6-B495-F20ACDFA7E67Q43898882-A081B991-F9CD-4AC6-8238-1CBEEBFBAF55Q45900950-9CDC539D-A02E-4A80-8CEF-CB7C13C9D224Q46844083-E259A3A5-B6A6-4754-A445-D81547D23087Q46852214-CF46E169-A052-4A25-8FDA-A85FA693E520Q47272524-8E76482C-EA17-4A01-8F49-BFFBEBAB64A6Q47759308-C66B86EC-D99E-46A1-8C24-B6E83889A226Q49834175-C3C7629F-2769-474C-8F5E-336C5EDD3629Q50054536-34863814-57F2-4C91-A749-0BE766AE9978
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mediators of ocular angiogenesis.
@en
Mediators of ocular angiogenesis.
@nl
type
label
Mediators of ocular angiogenesis.
@en
Mediators of ocular angiogenesis.
@nl
prefLabel
Mediators of ocular angiogenesis.
@en
Mediators of ocular angiogenesis.
@nl
P2093
P2860
P1433
P1476
Mediators of ocular angiogenesis.
@en
P2093
Balamurali K Ambati
Surekha Maddula
Yureeda Qazi
P2860
P2888
P304
P356
10.1007/S12041-009-0068-0
P577
2009-12-01T00:00:00Z